We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Woodcock Suggests Collaborative Biomarker-Based Clinical Trials
Drugmakers need to shift from phased, single-drug clinical trials toward a new paradigm of collaborative assessments of multiple drugs based on biomarkers, CDER Director Janet Woodcock said May 21, using the ongoing breast cancer trial I-Spy 2 as an illustrative example.